| Old Articles: <Older 6581-6590 Newer> |
|---|
 |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.   |
The Motley Fool
August 17, 2010
Travers & Jayson |
Interested in Cephalon ? Start Here! Every biotech company wants to discover the cure for cancer, Alzheimer's, or Wii knee. Every biotech investor hopes to catch the next Valeant Pharmaceuticals. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Biovail Last? Stop obsessing about the science. |
The Motley Fool
August 17, 2010
Travers & Jayson |
How Long Can Amylin Pharmaceuticals Last? You don't need an advanced degree in pharmacology to find biotech companies with a legitimate chance of hitting it big. |
The Motley Fool
August 17, 2010
Anders Bylund |
Agilent Made All the Right Moves Cut the dead weight and refocus on attractive markets? Sounds like a plan to me. |
The Motley Fool
August 17, 2010
Travers & Jayson |
Is Alexion Pharmaceuticals Burning Out? The first step toward finding a promising biotech company is not to figure out whether the science is any good, but to make sure that the company is financially healthy. |
The Motley Fool
August 16, 2010
Jim Mueller |
How Well Do You Use Cash, Medifast? Medifast had been much worse. The massive improvement is encouraging. |
The Motley Fool
August 16, 2010
Brian Orelli |
The Fine Line Between Saving Money and Making It Medco's trying to walk it. |
The Motley Fool
August 13, 2010
Brian Orelli |
Already a Slippery Slope for Eli Lilly The company gets a whiff of what its patent cliff might be like. |
The Motley Fool
August 13, 2010
Ilan Moscovitz |
Merck: Dividend Dynamo or Disaster? Just how safe is this dividend? |
| <Older 6581-6590 Newer> Return to current articles. |
